{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:52:15Z","timestamp":1768697535167,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ACOSOG-Z0011 and AMAROS trials showed that axillary lymph node dissection (ALND) provided no benefit for patients with 1\u20132 positive sentinel lymph nodes (+SLNs). There remains apprehension to omit ALND for patients in whom only 1\u20132 SLNs are retrieved and all are positive. This study evaluates current practices and pathological findings when ALND is pursued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We identified female patients with cT1\u20133N0 breast cancer who underwent sentinel lymphadenectomy from 2018 to 2021 in the National Cancer Database (NCDB). Patients with \u2264 2 SLNs were included and categorized on the basis of the number positive\/removed: 0\/1, 1\/1, 1\/2, and 2\/2. We assessed the rates and factors associated with ALND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 102,802 patients were included: 0\/1: 79,106 (77%), 1\/1: 10,549 (10%), 1\/2: 10,068 (10%), and 2\/2: 3079 (3%). ALND was most frequently performed for patients with 2\/2 +SLNs (41%), followed by 26% with 1\/1 +SLNs, 19% with 1\/2 +SLNs, and 6% with 0\/1 +SLNs. On multivariable analysis, 2\/2 +SLN status was the strongest independent predictor of ALND. For triple-negative and human epidermal growth factor receptor (HER)2+ patients, ALND did not affect adjuvant chemotherapy or radiation rates. Among pN+ hormone receptor (HR)+\/HER2\u2212 patients &gt; 50, ALND was linked to higher chemotherapy rates in all SLN groups, despite no difference in 21-gene recurrence scores. With a median follow-up of 35.4 months, ALND did not improve overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ALND is being performed at higher-than-expected rates in patients with \u2264 2 +SLNs and may contribute to adjuvant overtreatment, particularly in HR+\/HER2\u2212 patients. Multidisciplinary case discussions and ongoing provider education are essential to reduce unnecessary axillary interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18097-9","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T20:32:29Z","timestamp":1755981149000},"page":"9843-9856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management and Outcomes in Patients with Breast Cancer with 1-of-1 and 2-of-2 Positive Sentinel Nodes"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8831-9021","authenticated-orcid":false,"given":"Walker","family":"Lyons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. McAuley","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Bleicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison A.","family":"Aggon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alycia L.","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea S.","family":"Porpiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"6","key":"18097_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0960-7404(93)90064-6","volume":"2","author":"DN Krag","year":"1993","unstructured":"Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335\u20139. https:\/\/doi.org\/10.1016\/0960-7404(93)90064-6.","journal-title":"Surg Oncol."},{"issue":"3","key":"18097_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00000658-199409000-00015","volume":"220","author":"AE Giuliano","year":"1994","unstructured":"Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391\u20138. https:\/\/doi.org\/10.1097\/00000658-199409000-00015.","journal-title":"Ann Surg."},{"issue":"4","key":"18097_CR3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/SLA.0b013e3181c0e92a","volume":"251","author":"U Veronesi","year":"2010","unstructured":"Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4):595\u2013600. https:\/\/doi.org\/10.1097\/SLA.0b013e3181c0e92a.","journal-title":"Ann Surg."},{"issue":"10","key":"18097_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(10)70207-2.","journal-title":"Lancet Oncol."},{"issue":"10","key":"18097_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA."},{"issue":"12","key":"18097_CR6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.22.01565","volume":"41","author":"SAL Bartels","year":"2023","unstructured":"Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS Trial. J Clin Oncol. 2023;41(12):2159\u201365. https:\/\/doi.org\/10.1200\/JCO.22.01565.","journal-title":"J Clin Oncol."},{"issue":"9","key":"18097_CR7","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","volume":"29","author":"C Tinterri","year":"2022","unstructured":"Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29(9):5732\u201344. https:\/\/doi.org\/10.1245\/s10434-022-11866-w.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"18097_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryden L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390(13):1163\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2313487.","journal-title":"N Engl J Med."},{"key":"18097_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.breast.2019.03.002","volume":"45","author":"CA Garcia-Etienne","year":"2019","unstructured":"Garcia-Etienne CA, Mansel RE, Tomatis M, et al. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: impact of evidence on practice. Breast. 2019;45:89\u201396. https:\/\/doi.org\/10.1016\/j.breast.2019.03.002.","journal-title":"Breast."},{"issue":"5","key":"18097_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jsurg.2018.02.020","volume":"75","author":"NF Nocera","year":"2018","unstructured":"Nocera NF, Pyfer BJ, De La Cruz LM, Chatterjee A, Thiruchelvam PT, Fisher CS. NSQIP analysis of axillary lymph node dissection rates for breast cancer: implications for resident and fellow participation. J Surg Educ. 2018;75(5):1281\u20136. https:\/\/doi.org\/10.1016\/j.jsurg.2018.02.020.","journal-title":"J Surg Educ."},{"issue":"12","key":"18097_CR11","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al. Using the national cancer database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905.","journal-title":"JAMA Oncol."},{"issue":"6","key":"18097_CR12","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","volume":"26","author":"K Mallin","year":"2019","unstructured":"Mallin K, Browner A, Palis B, et al. Incident cases captured in the national cancer database compared with those in U.S. population based central cancer registries in 2012\u20132014. Ann Surg Oncol. 2019;26(6):1604\u201312. https:\/\/doi.org\/10.1245\/s10434-019-07213-1.","journal-title":"Ann Surg Oncol."},{"issue":"25","key":"18097_CR13","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2108873.","journal-title":"N Engl J Med."},{"issue":"3","key":"18097_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/lrb.2011.0007","volume":"9","author":"S Hayes","year":"2011","unstructured":"Hayes S, Di Sipio T, Rye S, et al. Prevalence and prognostic significance of secondary lymphedema following breast cancer. Lymphat Res Biol. 2011;9(3):135\u201341. https:\/\/doi.org\/10.1089\/lrb.2011.0007.","journal-title":"Lymphat Res Biol."},{"issue":"6","key":"18097_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(13)70076-7.","journal-title":"Lancet Oncol."},{"issue":"8","key":"18097_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2022.1628","volume":"8","author":"G Montagna","year":"2022","unstructured":"Montagna G, Zhang J, Sevilimedu V, et al. Risk Factors and racial and ethnic disparities in patients with breast cancer-related lymphedema. JAMA Oncol. 2022;8(8):1195\u2013200. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1628.","journal-title":"JAMA Oncol."},{"issue":"5","key":"18097_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331\u201357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035.","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"18097_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5.","journal-title":"Lancet Oncol."},{"issue":"7","key":"18097_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cncr.35136","volume":"130","author":"AD Williams","year":"2024","unstructured":"Williams AD, Ruth K, Shaikh SS, et al. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib? Cancer. 2024;130(7):1052\u201360. https:\/\/doi.org\/10.1002\/cncr.35136.","journal-title":"Cancer."},{"issue":"1","key":"18097_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41523-025-00757-4","volume":"11","author":"KN Wanis","year":"2025","unstructured":"Wanis KN, Dong W, Shen Y, et al. Predicting pathologic\u2265 N2 disease in women with breast cancer. NPJ Breast Cancer. 2025;11(1):46. https:\/\/doi.org\/10.1038\/s41523-025-00757-4.","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"18097_CR21","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1245\/aso.2003.03.015","volume":"10","author":"KJ Van Zee","year":"2003","unstructured":"Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140\u201351. https:\/\/doi.org\/10.1245\/aso.2003.03.015.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"18097_CR22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1245\/ASO.2005.06.037","volume":"12","author":"MC Specht","year":"2005","unstructured":"Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005;12(8):654\u20139. https:\/\/doi.org\/10.1245\/ASO.2005.06.037.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"18097_CR23","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1200\/JCO.2007.11.9479","volume":"26","author":"A Katz","year":"2008","unstructured":"Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol. 2008;26(13):2093\u20138. https:\/\/doi.org\/10.1200\/JCO.2007.11.9479.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18097-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:17:55Z","timestamp":1762352275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18097-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["18097"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18097-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}